Clinical Candidate: PSMA I&T
PNT2002 is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PSMA is overexpressed in the vast majority of prostate cancers (>85%), but very limited to normal tissues. Every year in the United States 52,000 men are either diagnosed with or progress to, mCRPC.
PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177. POINT has developed a unique radioactive API as well as formulation intellectual property for PNT2002.
Lantheus and POINT Biopharma have announced a strategic collaboration and exclusive license agreements for the commercialization of PNT2002.
PNT2002 is currently in the randomization stage of its Phase 3 study designed to evaluate superiority to the standard of care in mCRPC patients - learn more about the study at https://www.splashtrial.com.
PNT2001 is a next-generation PSMA-targeted radioligand.
Patients diagnosed with prostate cancer can live many years, increasing the risk of latent radiation toxicity appearing from off-target delivery of radiation. The current generation of PSMA-targeted radioligands is therefore unlikely to move earlier in disease treatment or be paired with more powerful radioisotopes like Actinium-225, due to concerns related to potential radiation toxicity.
PNT2001 attempts to address these concerns through unique linker technology that enables increased tumor accumulation, potentially enabling lower doses of radioisotope, reducing off-target toxicity without affecting tumor kill.
PNT2001 is currently in the preclinical stage of development.